Search Results

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis.

Enterprise Therapeutics Ltd announced that it has closed a £26 million Series B follow-on financing round, led by Panakes Partners.

Ludwig Enterprises, Inc is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma, an incurable brain cancer.

Leading health insurer and health care services company Humana Inc. announced that it has named David Dintenfass as President of Enterprise Growth.

Eli Lilly and Company announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly’s Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024.

Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that the company has received Continuing Review Approval on its planned clinical study from Advarra IRB, Columbia, MD.

Ludwig Enterprises, Inc. today announced the appointment of Scott Silverman as Chief Financial Officer (CFO).

Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) (“Scryb’’ or the “Company”) is pleased to announce the development of a new Artificial Intelligence (AI) software product, to enhance AI safety and trustworthiness for enterprises that are managing multiple AI systems, and provide management tools for compliance with impending AI regulation.

Sihuan Pharmaceutical Holdings Group Ltd. is pleased to announce that the “Group” was selected as one of the first echelon of enterprises in The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023.